Chemogenetic Tools and their Use in Studies of Neuropsychiatric Disorders

被引:1
作者
Neroldova, Marketa [1 ]
Stuchlik, Ales [1 ]
机构
[1] Czech Acad Sci, Lab Neurophysiol Memory, Inst Physiol, Prague, Czech Republic
关键词
Chemogenetics; DREADDs; PSAMs; Neuropsychiatric disorders; ALLOTHETIC PLACE AVOIDANCE; CHEMICAL-GENETIC APPROACH; VENTRAL TEGMENTAL AREA; DOPAMINE NEURONS; NUCLEOTIDE SPECIFICITY; RECEPTOR ANTAGONIST; NUCLEUS-ACCUMBENS; IN-VITRO; ACTIVATION; MICE;
D O I
10.33549/physiolres.935401
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Chemogenetics is a newly developed set of tools that allow for selective manipulation of cell activity. They consist of a receptor mutated irresponsive to endogenous ligands and a synthetic ligand that does not interact with the wild-type receptors. Many different types of these receptors and their respective ligands for inhibiting or excitating neuronal subpopulations were designed in the past few decades. It has been mainly the G-protein coupled receptors (GPCRs) selectively responding to clozapine-N-oxide (CNO), namely Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), that have been employed in research. Chemogenetics offers great possibilities since the activity of the receptors is reversible, inducible on demand by the ligand, and non-invasive. Also, specific groups or types of neurons can be selectively manipulated thanks to the delivery by viral vectors. The effect of the chemogenetic receptors on neurons lasts longer, and even chronic activation can be achieved. That can be useful for behavioral testing. The great advantage of chemogenetic tools is especially apparent in research on brain diseases since they can manipulate whole neuronal circuits and connections between different brain areas. Many psychiatric or other brain diseases revolve around the dysfunction of specific brain networks. Therefore, chemogenetics presents a powerful tool for investigating the underlying mechanisms causing the disease and revealing the link between the circuit dysfunction and the behavioral or cognitive symptoms observed in patients. It could also contribute to the development of more effective treatments.
引用
收藏
页码:S449 / S470
页数:22
相关论文
共 105 条
[11]   Chemogenetic Activation of Midbrain Dopamine Neurons Affects Attention, but not Impulsivity, in the Five-Choice Serial Reaction Time Task in Rats [J].
Boekhoudt, Linde ;
Voets, Elisa S. ;
Flores-Dourojeanni, Jacques P. ;
Luijendijk, Mieneke C. M. ;
Vanderschuren, Louk J. M. J. ;
Adan, Roger A. H. .
NEUROPSYCHOPHARMACOLOGY, 2017, 42 (06) :1315-1325
[12]   Chemogenetic activation of dopamine neurons in the ventral tegmental area, but not substantia nigra, induces hyperactivity in rats [J].
Boekhoudt, Linde ;
Omrani, Azar ;
Luijendijk, Mieneke C. M. ;
Wolterink-Donselaar, Inge G. ;
Wijbrans, Ellen C. ;
van der Plasse, Geoffrey ;
Adan, Roger A. H. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (11) :1784-1793
[13]   Activation of Nigrostriatal Dopamine Neurons during Fear Extinction Prevents the Renewal of Fear [J].
Bouchet, Courtney A. ;
Miner, Megan A. ;
Loetz, Esteban C. ;
Rosberg, Adam J. ;
Hake, Holly S. ;
Farmer, Caroline E. ;
Ostrovskyy, Mykola ;
Gray, Nathan ;
Greenwood, Benjamin N. .
NEUROPSYCHOPHARMACOLOGY, 2018, 43 (03) :665-672
[14]   Reverse Pharmacogenetic Modulation of the Nucleus Accumbens Reduces Ethanol Consumption in a Limited Access Paradigm [J].
Cassataro, Daniela ;
Bergfeldt, Daniella ;
Malekian, Cariz ;
Van Snellenberg, Jared X. ;
Thanos, Panayotis K. ;
Fishell, Gord ;
Sjulson, Lucas .
NEUROPSYCHOPHARMACOLOGY, 2014, 39 (02) :283-290
[15]   A chemical-genetic approach to studying neurotrophin signaling [J].
Chen, X ;
Ye, HH ;
Kuruvilla, R ;
Ramanan, N ;
Scangos, KW ;
Zhang, C ;
Johnson, NM ;
England, PM ;
Shokat, KM ;
Ginty, DD .
NEURON, 2005, 46 (01) :13-21
[16]   The First Structure-Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs [J].
Chen, Xin ;
Choo, Hyunah ;
Huang, Xi-Ping ;
Yang, Xiaobao ;
Stone, Orrin ;
Roth, Bryan L. ;
Jin, Jian .
ACS CHEMICAL NEUROSCIENCE, 2015, 6 (03) :476-484
[17]   Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice [J].
Chiang, Angie C. A. ;
Fowler, Stephanie W. ;
Savjani, Ricky R. ;
Hilsenbeck, Susan G. ;
Wallace, Clare E. ;
Cirrito, John R. ;
Das, Pritam ;
Jankowsky, Joanna L. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 215 (05) :1349-1364
[18]   Artificial metalloenzymes for enantioselective catalysis based on biotin-avidin [J].
Collot, J ;
Gradinaru, J ;
Humbert, N ;
Skander, M ;
Zocchi, A ;
Ward, TR .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (30) :9030-9031
[19]   Controlling signaling with a specifically designed Gi-coupled receptor [J].
Coward, P ;
Wada, HG ;
Falk, MS ;
Chan, SDH ;
Meng, F ;
Akil, H ;
Conklin, BR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) :352-357
[20]   β-arrestins and cell signaling [J].
DeWire, Scott M. ;
Ahn, Seungkirl ;
Lefkowitz, Robert J. ;
Shenoy, Sudha K. .
ANNUAL REVIEW OF PHYSIOLOGY, 2007, 69 :483-510